About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘oncology retractions’ Category

Failure to disclose drug company sponsor among litany of reasons for cancer retraction

leave a comment »

tumor biologyThis one’s a real mess.

In June, a paper in Tumor Biology was retracted for at least four reasons, including bad data and hiding a trial sponsor (Merck). Some people who contributed work weren’t cited; at least one author had no idea his name would be on it. And that’s just what they tell us in the notice.

Here’s the notice for “Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China:” Read the rest of this entry »

About these ads

Authors retract HER-2 endometrial cancer paper for 2x publication

with 4 comments

OGSFile this one under strange excuses.

A cancer paper was retracted on September 17 for a double publication. According to the notice in which the authors admit to duplicating the “opening to the readers,” which we assume is the introduction, there was no need to cite the article “because it had not yet been printed at that time.”

Here’s the notice for “The effect of HER-2 polymorphism according to age on the risk and pathologic feature of endometrial cancer”: Read the rest of this entry »

Cell line switch sinks PLoS ONE cancer paper

with 4 comments

plosWe’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.

Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.

Here’s the notice for “Epithelial Mesenchymal Transition Is Required for Acquisition of Anoikis Resistance and Metastatic Potential in Adenoid Cystic Carcinoma”:
Read the rest of this entry »

Yet another study of widely touted cancer “cure” retracted

with 7 comments

cancer immunology immunotherapyA third study of GcMAF, a protein being used to treat a variety of conditions from AIDS to autism to cancer, all without the blessing of health agencies, has been retracted.

Here’s the notice in Cancer Immunology, Immunotherapy for “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF:” Read the rest of this entry »

Former UT-Southwestern cancer researchers faked data in 10 papers: ORI

with 14 comments

ut southwesternThe Office of Research Integrity (ORI) has ruled in a case we’ve been following for nearly two years — and which seems to have been launched after Retraction Watch readers took a careful look at figures from what appeared to be an unrelated case.

Takao Takahashi and Makato Suzuki, both former postdocs at a cancer research center at UT-Southwestern, both “knowingly, intentionally, and recklessly falsified data” in a total of 10 papers, according to the ORI. Takahashi, now at Gifu University in Japan, was responsible for fakery in four papers, while Suzuki, now at Kumamoto University Hospital, also in Japan, falsified data in six.

We reported on the retraction of the four Takahashi papers, and one of the Suzuki papers, in November 2012. At that time, Adi Gazdar, the head of the lab where the researchers worked, told us that
Read the rest of this entry »

Written by Ivan Oransky

September 18, 2014 at 7:58 am

Fudged figures sink breast cancer paper

with 22 comments

oncogeneA prestigious cancer journal has pulled an article over “concerns” regarding some of the figures, which PubPeer commenters had tagged as suspect.

A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.

Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »

Cancer researcher has correction upgraded to retraction

with 11 comments

mol endo coverRakesh Kumar, a researcher with six recent corrections and one retraction, has had one of those corrections upgraded to a retraction.

Here’s the unhelpful notice, from Molecular Endocrinology: Read the rest of this entry »

Follow

Get every new post delivered to your Inbox.

Join 35,846 other followers